Profile data is unavailable for this security.
About the company
Pulmatrix, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat respiratory and other diseases with important unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders, such as acute migraine and serious lung diseases, such as chronic obstructive pulmonary disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). The Company’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes. The Company’s therapeutic candidates include PUR3100, PUR1800, and PUR1900. PUR3100 is the iSPERSE formulation of dihydroergotamine (DHE), for the treatment of acute migraine.
- Revenue in USD (TTM)10.01m
- Net income in USD-9.66m
- Incorporated2013
- Employees22.00
- LocationPulmatrix Inc945 CONCORD STREET, SUITE 1217FRAMINGHAM 01701United StatesUSA
- Phone+1 (781) 357-2333
- Fax+1 (302) 636-5454
- Websitehttps://www.pulmatrix.com/
More ▼
Mergers & acquisitions
| Acquired company | PULM:NAQ since announced | Transaction value |
|---|---|---|
| Cullgen Inc | 209.51% | 280.00m |
Data delayed at least 15 minutes, as of Nov 21 2024 20:32 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kairos Pharma Ltd | 0.00 | -2.74m | 18.75m | -- | -- | 5.63 | -- | -- | -0.2279 | -0.2279 | 0.00 | 0.2594 | 0.00 | -- | -- | -- | -92.10 | -- | -264.70 | -- | -- | -- | -- | -- | -- | -2.61 | 0.0409 | -- | -- | -- | -72.57 | -- | -- | -- |
| Neurosense Therapeutics Ltd | 0.00 | -7.51m | 19.28m | 16.00 | -- | -- | -- | -- | -0.4392 | -0.4392 | 0.00 | -0.0943 | 0.00 | -- | -- | 0.00 | -154.72 | -- | -470.03 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 18.10 | -- | -- | -- |
| Unity Biotechnology Inc | 0.00 | -19.05m | 19.71m | 19.00 | -- | 1.39 | -- | -- | -1.14 | -1.14 | 0.00 | 0.8394 | 0.00 | -- | -- | 0.00 | -32.73 | -47.21 | -38.49 | -53.51 | -- | -- | -- | -6,395.92 | -- | -- | 0.00 | -- | -100.00 | -- | 10.36 | -- | -61.28 | -- |
| Forte Biosciences Inc | 0.00 | -34.20m | 19.79m | 11.00 | -- | 2.11 | -- | -- | -20.00 | -20.00 | 0.00 | 6.42 | 0.00 | -- | -- | 0.00 | -103.90 | -72.06 | -137.40 | -82.27 | -- | -- | -- | -491,850.00 | -- | -- | 0.00 | -- | -- | -- | -126.79 | -- | -46.29 | -- |
| Goldenwell Biotech Inc | 940.00 | -137.11k | 19.80m | -- | -- | 5,169.71 | -- | 21,063.83 | -0.0014 | -0.0014 | 0.00001 | 0.00004 | 0.0048 | 0.0031 | -- | -- | -69.82 | -- | -70.29 | -- | 42.55 | -- | -14,586.17 | -- | 21.43 | -- | 0.00 | -- | -95.10 | -- | 88.13 | -- | -- | -- |
| Ibio Inc | 175.00k | -14.36m | 20.01m | 16.00 | -- | 1.07 | -- | 114.35 | -3.97 | -6.65 | 0.0307 | 2.06 | 0.0056 | -- | -- | 10,937.50 | -46.17 | -27.69 | -75.53 | -33.13 | -- | -- | -8,204.57 | -1,862.11 | -- | -- | 0.0736 | -- | -- | -35.52 | 47.31 | -- | -26.66 | -- |
| OpGen Inc | 1.96m | -22.39m | 20.04m | 100.00 | -- | -- | -- | 10.20 | -20.01 | -20.01 | 1.66 | -8.65 | 0.1553 | -- | 6.09 | -- | -176.99 | -87.95 | -15,455.17 | -127.65 | 3.15 | 15.42 | -1,139.66 | -794.78 | -- | -20.25 | -- | -- | 31.11 | 3.02 | 12.38 | -- | 40.20 | -- |
| Spruce Biosciences Inc | 7.10m | -39.43m | 20.24m | 22.00 | -- | 0.3919 | -- | 2.85 | -0.9598 | -0.9598 | 0.1728 | 1.25 | 0.0798 | -- | -- | 244,862.10 | -44.28 | -41.24 | -55.51 | -46.49 | -- | -- | -555.23 | -1,774.39 | -- | -121.12 | 0.0399 | -- | -- | -- | -3.77 | -- | -- | -- |
| Pulmatrix Inc | 10.01m | -9.66m | 20.53m | 22.00 | -- | 1.88 | -- | 2.05 | -2.64 | -2.64 | 2.74 | 2.99 | 0.4145 | -- | 23.16 | 454,772.70 | -40.00 | -46.91 | -44.64 | -58.12 | -- | -- | -96.51 | -238.04 | -- | -- | 0.00 | -- | 20.21 | 116.62 | 25.03 | -- | 104.29 | -- |
| Neurobo Pharmaceuticals Inc | 0.00 | -27.73m | 20.68m | 8.00 | -- | 1.60 | -- | -- | -4.77 | -4.77 | 0.00 | 1.50 | 0.00 | -- | -- | 0.00 | -114.20 | -95.57 | -159.68 | -135.64 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 10.72 | -- | 75.54 | -- |
| Cocrystal Pharma Inc | 0.00 | -18.70m | 20.96m | 12.00 | -- | 1.65 | -- | -- | -1.84 | -1.84 | 0.00 | 1.25 | 0.00 | -- | -- | 0.00 | -76.57 | -50.94 | -83.17 | -52.77 | -- | -- | -- | -1,501.78 | -- | -- | 0.00 | -- | -- | -- | 53.69 | -- | 33.34 | -- |
| Pieris Pharmaceuticals Inc | 1.35m | -15.95m | 21.14m | 46.00 | -- | 1.30 | -- | 15.63 | -12.61 | -12.61 | 1.06 | 12.32 | 0.0338 | -- | 1.91 | 29,391.30 | -39.93 | -28.41 | -68.21 | -39.69 | -- | -- | -1,179.96 | -94.61 | -- | -- | 0.00 | -- | 65.28 | 8.03 | 26.25 | -- | -36.82 | -- |
| GlycoMimetics Inc | 10.00k | -39.74m | 21.28m | 35.00 | -- | 1.87 | -- | 2,127.97 | -0.6165 | -0.6165 | 0.0002 | 0.1764 | 0.0003 | -- | 0.0836 | 285.71 | -115.34 | -43.60 | -136.58 | -47.82 | -- | -- | -397,350.50 | -2,243.52 | -- | -- | 0.00 | -- | -86.67 | -- | 20.97 | -- | -29.82 | -- |
| Bolt Biotherapeutics Inc | 9.78m | -65.09m | 21.81m | 100.00 | -- | 0.3029 | -- | 2.23 | -1.71 | -1.71 | 0.2567 | 1.88 | 0.0687 | -- | -- | 97,790.00 | -45.72 | -48.32 | -52.52 | -54.03 | -- | -- | -665.56 | -2,267.00 | -- | -- | 0.00 | -- | 37.48 | -- | 21.45 | -- | -6.61 | -- |
| Aeon Biopharma Inc | 0.00 | -350.57m | 22.27m | 5.00 | -- | -- | -- | -- | -9.61 | -9.61 | 0.00 | -0.8106 | 0.00 | -- | -- | 0.00 | -3,242.54 | -- | -- | -- | -- | -- | -- | -- | -- | 2.94 | -- | -- | -- | -- | -631.85 | -- | -- | -- |
Data as of Nov 21 2024. Currency figures normalised to Pulmatrix Inc's reporting currency: US Dollar USD
7.24%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Renaissance Technologies LLCas of 30 Sep 2024 | 117.22k | 3.21% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 54.90k | 1.50% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 35.08k | 0.96% |
| Geode Capital Management LLCas of 30 Sep 2024 | 29.58k | 0.81% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 13.95k | 0.38% |
| Citadel Securities LLCas of 30 Sep 2024 | 10.34k | 0.28% |
| Tower Research Capital LLCas of 30 Sep 2024 | 2.96k | 0.08% |
| UBS Securities LLCas of 30 Sep 2024 | 227.00 | 0.01% |
| UBS Financial Services, Inc.as of 30 Sep 2024 | 165.00 | 0.01% |
| American Portfolios Advisors, Inc.as of 30 Sep 2024 | 50.00 | 0.00% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
